| Ytd | 176.50% | |
| 1y | 258.74% |
| Open | 9.27 | Prev Close | 9.27 | Low | 9.08 | High | 9.74 | Mkt Cap | 1.66B |
| Vol | 7.73M | Avg Vol | 4.45M | EPS | -0.79 | P/E | N/A | Forward P/E | -14.29 |
| Beta | 2.44 | Short Ratio | 13.57 | Inst. Own | 87.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 8.75 | 200-d Avg | 5.53 | 1yr Est | 14.40 |
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal.
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcr
Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by h
Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androg
Bank of America Corp DE raised its holdings in Absci Corporation (NASDAQ: ABSI) by 55.2% in the unde
VANCOUVER, Wash. and NEW YORK, Sept.
On August 14, 2026, Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) filed its first-ever
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing
U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 re
Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targe
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday'
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.21) per share which missed the analyst consensu
Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million u
Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch g
Here is how Absci Corporation (ABSI) and Acadia Healthcare (ACHC) have performed compared to their s
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to W
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in AB
Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let'
Truist Securities analyst Srikripa Devarakonda maintains Absci (NASDAQ:ABSI) with a Buy and raise
Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pha
Top analysts changed outlook on top names. See full changes, upgrades, downgrades on analyst ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Absci (NASDAQ:ABSI) with a Buy a
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's reg
U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares j
Absci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported posi
Absci reported positive interim Phase 1 ABS-201 data and priced a $100 million stock offering to adv
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
The gross proceeds from the offering, before deducting underwriting discounts and commissions and of
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investmen
Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of t
Study medication appears well tolerated, with favorable safety data across all blinded single ascend
Guggenheim analyst Vamil Divan maintains Absci (NASDAQ:ABSI) with a Buy and raises the price targ
Stocks had mixed performance on Thursday, Dow Jones up 793 points while Nasdaq down 232 points. Rumb
Leerink Partners analyst Mani Foroohar initiates coverage on Absci (NASDAQ:ABSI) with a Outperfor
Top analysts change outlook on top names. Check out analyst ratings page for all changes. RMIX, ABSI
BTIG analyst Kambiz Yazdi initiates coverage on Absci (NASDAQ:ABSI) with a Buy rating and announc
AMD discloses a new position in Marvell Technology in its latest 13F filing, revealing a stake that
Truist Securities analyst Srikripa Devarakonda maintains Absci (NASDAQ:ABSI) with a Buy and raise
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.19) per share which beat the analyst consensus
U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining
Blaize Holdings Inc (BZAI) gained 41.3% in pre-market trading after reporting better-than-expected q
Absci (NASDAQ:ABSI) reported quarterly losses of $(0.20) per share which met the analyst consensus e